Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.

Blood
Carl E AllenMichael A Pulsipher

Abstract

Allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning for disorders associated with excessive inflammation such as hemophagocytic lymphohistiocytosis (HLH) is associated with early mortality. A multicenter prospective phase 2 trial of reduced-intensity conditioning with melphalan, fludarabine, and intermediate-timing alemtuzumab was conducted for HLA matched or single HLA locus mismatched related or unrelated donor HCT in a largely pediatric cohort. Graft-versus-host disease (GVHD) prophylaxis was cyclosporine with methylprednisolone. The primary end point was 1-year overall survival (OS). Thirty-four patients with HLH and 12 with other primary immune deficiencies were transplanted. With a median follow-up of 20 months, the 1-year OS for transplanted patients was 80.4% (90% confidence interval [CI], 68.6%-88.2%). Five additional deaths by 16 months yielded an 18-month OS probability of 66.7% (90% CI, 52.9%-77.3%). Two patients experienced primary graft failure, and 18 patients either experienced a secondary graft failure or required a second intervention (mostly donor lymphocyte infusion [DLI]). At 1 year, the proportion of patients alive with sustained engraftment without DLI or second HCT was 39....Continue Reading

References

Aug 13, 2002·Cytotherapy·P RebelloG Hale
Dec 14, 2004·Bone Marrow Transplantation·S ShenoyR J Hayashi
Aug 29, 2006·Pediatric Blood & Cancer·Jan-Inge HenterGritta Janka
Dec 14, 2007·British Journal of Haematology·AnnaCarin HorneUNKNOWN Histiocyte Society
Jan 13, 2009·Pediatric Blood & Cancer·Patrick A ThompsonKenneth L McClain
May 25, 2010·Immunology and Allergy Clinics of North America·Reinhard A Seger
Nov 15, 2011·The Journal of Allergy and Clinical Immunology·Caridad A MartinezRobert A Krance
Sep 17, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Rebecca A MarshAlexandra H Filipovich
Oct 29, 2013·Lancet·Tayfun GüngörUNKNOWN Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation
Sep 10, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Lauri M BurroughsAnn E Woolfrey
Nov 13, 2015·The Journal of Allergy and Clinical Immunology·Zeynep Yesim KucukAlexandra H Filipovich
Oct 5, 2016·The Journal of Allergy and Clinical Immunology·M Teresa de la MorenaChaim M Roifman
Jan 17, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Rebecca A MarshParinda A Mehta
Jun 5, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Allistair AbrahamShalini Shenoy
Jun 26, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sachit A PatelSuhag H Parikh

❮ Previous
Next ❯

Citations

May 28, 2019·Frontiers in Pediatrics·Jessica A NeelyKristin Ammon Shimano
Jul 2, 2019·NeoReviews·Erin Hall, Shalini Shenoy
Nov 12, 2019·Frontiers in Pediatrics·Kai LehmbergClaire Booth
Feb 29, 2020·Blood·Scott W Canna, Rebecca A Marsh
Nov 20, 2019·Current Allergy and Asthma Reports·S H LumM A Slatter
Sep 29, 2018·Blood·Sarah Nikiforow
Sep 12, 2019·Frontiers in Pediatrics·Ottavia Maria DelmonteLuigi Daniele Notarangelo
May 7, 2020·The New England Journal of Medicine·Franco LocatelliCristina de Min
Sep 8, 2020·Pediatric Blood & Cancer·Zhongbo Hu, Jignesh Dalal
Jan 8, 2019·Pediatric Investigation·Theodore B Moore
Jun 5, 2020·Pediatric Transplantation·Christina Oikonomopoulou, Evgenios Goussetis
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven M Devine, Mary M Horowitz
Dec 23, 2020·Blood Advances·Pietro MerliFranco Locatelli
Mar 10, 2021·Expert Review of Clinical Pharmacology·Chiara GaronziSimone Cesaro
Feb 9, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·John E LevineNancy DiFronzo
Jun 14, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Cristina F ContrerasChristopher C Dvorak
Mar 21, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Holly WobmaPrakash Satwani
Jul 7, 2021·Bone Marrow Transplantation·A C LankesterUNKNOWN Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation and the European Society for Immune
Aug 11, 2021·The Journal of Allergy and Clinical Immunology·Rebecca A MarshMary Eapen
Oct 9, 2021·Nature Reviews. Disease Primers·Kenneth L McClainCarl E Allen
Jun 3, 2021·Blood·Siobhan O Burns, Emma C Morris
Dec 16, 2021·Current Opinion in Pediatrics·Corina Gonzalez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.